Seraing, January 31, 2019 – Syngulon announces the issuance by the USPTO on January 29, 2019 of US Patent 10,188,114 covering the use of bacteriocin/immunity for controlled growth of microorganisms.
On May 10, 2016 the USPTO issued a first patent to Syngulon (US Patent 9,333,227) for the use of bacteriocin/immunity in any bacteria, yeast or algae for controlled growth of microorganisms.
These issued patents are part of a worldwide patent portfolio developed by Syngulon and are available for licensing in all fields of use on a non-exclusive base.
The inventor of these two patents is Dr Philippe Gabant, Co-Founder and Chief Scientific Officer of Syngulon, one of the pioneers in the development of selection technologies. Dr Philippe Gabant is co-inventor of US patents 5,910,438 / 6,180,407 / 7,176,029 licensed on an exclusive base to Invitrogen for the selection of recombinant plasmids. Dr Philippe Gabant is also co-inventor of US patent 8,470,580 for production of recombinant protein that has been licensed on non-exclusive base to Sanofi Pasteur, GSK and Merck.
This new patent of Syngulon, US 10,188,114, covers “A method of controlling the growth of a second microbial cell” […] “comprising: allowing a recombinantly engineered first microbial cell to proliferate in a culture medium” […] “wherein said second microbial cell interferes with the fermenting of said culture medium” […] with “first microbial cell comprising a first nucleic acid encoding a bacteriocin operably linked to a promoter, the method further comprising expressing and secreting the bacteriocin into the culture medium, wherein the bacteriocin is selected to inhibit or prevent the reproduction of the second microbial cell”
Syngulon is a synthetic biology startup developing original genetic technologies using bacteriocins. The team of scientists works in different academic partner laboratories and R&D programs involve partners from Belgium, Brazil, France, Germany, The Netherlands, and the UK. Syngulon owns a collection of natural and synthetic bacteriocins. Syngulon is generating a patent portfolio of genetic technologies to solve key issues:
- Gene containment
- Yield increase
- Contamination prevention
- Genetic drift
- Antibiotic-free selection of expressing clones